Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10065067 | 0.92 | L3MBTL1 (0.56) | MAPTHTTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL2752744 | 0.85 | FFAR1 (0.51) | MAPTHTTFFAR1 | |
| SCHEMBL10065109 | 0.84 | NOTUM (0.56) | NPSR1FFAR1 | |
| SCHEMBL10065065 | 0.83 | HTT (0.70) | MAPTHTTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL10175709 | 0.83 | KDM4E (0.61) | MAPTHTTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL10065073 | 0.83 | NPSR1 (0.49) | HTTNPSR1FFAR1 | |
| SCHEMBL10065684 | 0.83 | NPSR1 (0.49) | HTTNPSR1FFAR1 | |
| SCHEMBL10065111 | 0.83 | NPSR1 (0.68) | MAPTALDH1A1GAANPSR1PKM | |
| SCHEMBL10065721 | 0.82 | HTT (0.52) | MAPTHTTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL10064815 | 0.82 | KMT2A (0.64) | MAPTHTTL3MBTL1ALDH1A1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648038-B2 | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments | SANOFI (FR) | 2014-02-11 | — | — | US | disclosed |
| WO-2012004269-A1 | (2-ARYLOXY-ACETYLAMINO)-PHENYL-PROPIONIC ACID DERIVATIVES, METHOD FOR PRODUCING SAME AND USE THEREOF AS PHARMACEUTICALS | SANOFI (FR) | 2012-01-12 | — | — | WO | disclosed |
| US-20120004167-A1 | (2-ARYLOXYACETYLAMINO) PHENYLPROPIONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004167-A1 | (2-ARYLOXYACETYLAMINO) PHENYLPROPIONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS | GPR119, DPP9, DPP7 | MAPT 4470/4885HTT 3157/4885L3MBTL1 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.